Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Return on Sales (2023 - 2025)

CG Oncology's Return on Sales history spans 3 years, with the latest figure at 17.77% for Q4 2025.

  • For Q4 2025, Return on Sales rose 5198.0% year-over-year to 17.77%; the TTM value through Dec 2025 reached 39.81%, up 3749.0%, while the annual FY2025 figure was 39.81%, 3749.0% up from the prior year.
  • Return on Sales reached 17.77% in Q4 2025 per CGON's latest filing, up from 26.24% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 17.77% in Q4 2025 to a low of 16551.0% in Q4 2023.
  • Average Return on Sales over 3 years is 1780.73%, with a median of 170.36% recorded in 2024.
  • Peak YoY movement for Return on Sales: skyrocketed 1648125bps in 2024, then tumbled -63064bps in 2025.
  • A 3-year view of Return on Sales shows it stood at 16551.0% in 2023, then skyrocketed by 100bps to 69.75% in 2024, then surged by 75bps to 17.77% in 2025.
  • Per Business Quant, the three most recent readings for CGON's Return on Sales are 17.77% (Q4 2025), 26.24% (Q3 2025), and 232.46% (Q2 2025).